A promising dendritic cell (DC) therapy currently in clinical trials is displaying the potential to revolutionize the multiple myeloma treatment paradigm. If successful, its growth will be facilitated by an increasing embrace of personalized medicine for the research and development of DC therapies. Against this backdrop, the multiple myeloma dendritic cell therapy sales across the eight major markets (8MM*) are set to reach $62 million in 2031, forecasts GlobalData, a leading data and analytics company.

Multiple myeloma (MM), the second most common hematological malignancy, has had a rapidly evolving treatment landscape in the past decade. In recent years, newer classes of therapy have ushered in a new chapter for MM treatment, as well as monoclonal antibodies, bispecific antibodies, immune checkpoint inhibitors, and adoptive T cell therapies, with some of them achieving notable clinical breakthroughs in MM patients.

However, despite the recent strides, a significant portion of patients still relapse, and the effectiveness of these treatments is hindered by immune evasion mechanisms and an immunosuppressive bone marrow microenvironment. Following the successful Phase I study results published in Clinical Cancer Research on 22 September regarding DC Survivin Vaccine in development by the Moffitt Cancer Centre,  DC therapies are increasingly garnering attention for MM.

Verona Morina, Oncology and Hematology Analyst at GlobalData, comments: “The primary objective of the DC approaches is to trigger or enhance tumor-specific T-cell immunity against cancer cells, relying on antigen-driven mechanisms. The goal is not only to achieve an anti-tumor response but also to establish enduring protection against potential disease recurrence, which will undoubtedly revolutionize MM treatment as there is an unmet need to effectively address the recurrence of tumor growth.”

“If successful, the DC Survivin vaccine will face extreme competition as there is a heavily crowded treatment landscape, with new generation therapies such as bispecific antibodies including Tecvayli and Blenrep becoming well established and favored.”

DC therapies also carry a substantial cost and involve a relatively extended production process, creating further obstacles to their adoption for treatment. Yet the novelty associated with harnessing the patient’s immune system to get them into remission and potentially keep the cancer from coming back is a strategy which may offer the DC Survivin Vaccine a decent share of this market if it secures approval in the future.

Morina concludes: “The increasing embrace of personalized medicine, rising government backing for the research and development of DC therapies, and heightened awareness among healthcare professionals and patients about the potential advantages of DC therapies would drive market expansion.”

*8MM: The US, 5EU (France, Germany, Italy, Spain, the UK), Japan, and Canada.